Clinical Trial Update: A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia [Phase 3]

View source ↗

Summary

Phase 3 study of lanabecestat (LY3314814) in early Alzheimer's disease dementia was terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• lanabecestat (lanabecestat)

Snippet

Sponsor: AstraZeneca | Conditions: Alzheimer's Disease | Phase 3 | Status: TERMINATED | Results posted: 2019-07-05